The Medicrea Group announced the filing of its 510(k) submission to the U.S. Food and Drug Administration for approval of the company’s 3D-printed Titanium interbody devices, with compatible UNiD™ Lab personalized surgical planning and analytical services. The company’s deep expertise with digital surgical modeling, combined with the precise inventory control afforded by in-house 3D-printing technology, enables Medicrea to personalize the implant selection and alignment requirements for each patient prior to surgery in order to achieve an iterative procedural cycle, thereby increasing surgical efficiency, streamlining inventory requirements and significantly reducing the high number of costly revision surgeries currently experienced in traditional spinal surgery. The company first introduced its comprehensive, service-based approach to personalized spine with UNiD™ Rod technology, the first patient-specific spinal implant to be FDA-cleared in late 2014, which recently surpassed 1,100 procedures at the end of 2016. With the development of 3D-printed Titanium technology and compatible UNiD™ Lab services, the company continues to transform the relationship between healthcare providers and device manufacturers in the spine industry by creating a collaborative interaction that results in reliable, data-driven personalized patient care.